Citations 336
Faculty Opinions recommendation of A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.
Borad, Mitesh J.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 3, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available
Faculty Opinions recommendation of Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers.
Borad, Mitesh J.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 3, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available
Faculty Opinions recommendation of Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.
Borad, Mitesh J.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 3, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available
Faculty Opinions recommendation of Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
Borad, Mitesh J.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 2, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available
Faculty Opinions recommendation of Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.
Borad, Mitesh J.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 2, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available
Faculty Opinions recommendation of A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.
Borad, Mitesh J.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 2, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available
Faculty Opinions recommendation of Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy.
Borad, Mitesh J.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 30, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available
Faculty Opinions recommendation of TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
Borad, Mitesh J.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 30, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available
Faculty Opinions recommendation of Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer.
Borad, Mitesh J.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 30, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available
Faculty Opinions recommendation of Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.
Borad, Mitesh J.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 29, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available